Fig. 3

The anti-leukemic activity of WP1130 and its effect on WT1 protein. a THP1 and Kasumi-1 cells (2 × 10³) were treated with or without WP1130 (5.0 µM) and were plated on methylcellulose medium. Colonies were counted after 2 weeks. ^**and ^##P < 0.01. b BM CD34⁺ cells from four AML patients were isolated and incubated with or without WP1130 (5.0 µM). These cells (5 × 10³) were plated on methylcellulose medium, and colonies were scored after 2 weeks. ^**P < 0.01. Shown are the representative pictures showing colonies (left) and statistical analysis of scored colonies (right). Bar represents 50 µm. c Apoptosis was measured in normal CD34⁺ cells isolated from umbilical cord blood and treated with or without WP1130 (5.0 µM) for 24 h. d Colonies formed by CD34⁺ cells (2 × 10³) treated with or without 5.0 μM WP1130 were scored. e and f THP1 and Kasumi-1 cells were treated with 1.25, 2.5, and 5.0 μM WP1130 for 24 h (left blots) or treated with 5.0 μM WP1130 for 2, 4, 8, 16, and 24 h (right blots). WT1 protein expression was assessed by Western blot. g WT1 protein levels were measured in primary blasts from four AML patients incubated with WP1130 (5.0 µM) for 24 h. h The transcripts of WT1 were measured in THP1 and Kasumi-1 cells treated with 2.5 and 5.0 μM WP1130 for 24 h. i The transcripts of WT1 were measured in BM blasts from four AML patients incubated with or without WP1130 (5.0 µM) for 24 h